Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on June 15, 2022. The filing reports on a material amendment to a previously disclosed Merger Agreement with Nano Precision Medical, Inc. (NPM), originally entered into on February 4, 2022.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial disclosure relates to the terms of the merger agreement:
- Available Cash Requirement: The required available cash for the merger has been decreased to $63 million.
- Adjustments: This amount is subject to reduction by any advances made by Second Sight to NPM for working capital.
Material Changes Versus Prior Period
On June 15, 2022, NPM granted a waiver to Second Sight Medical Products, Inc. This waiver amends the original Merger Agreement by lowering the available cash requirement. The filing does not contain comparative financial data against prior periods as it is a current report regarding a specific corporate transaction rather than a periodic financial statement.
Guidance, Outlook, and Risks
Transaction Status: The proposed business combination is the subject of a registration statement on Form S-4, which includes a proxy statement/prospectus. Investors are directed to review the Form S-4 for full details on benefits and risks.
Regulatory and Legal Disclosures:
- The communication is for informational purposes only and does not constitute an offer to buy or sell securities.
- No offer of securities will be made except via a prospectus meeting Section 10 of the Securities Act of 1933.
- Company directors and executive officers are deemed participants in the proxy solicitation.
Important Facts for Investor Verification
- Verify the final terms of the merger by reviewing the Form S-4 registration statement and the definitive proxy statement/prospectus.
- Confirm the exact amount of any working capital advances made by Second Sight to NPM, as these reduce the $63 million cash requirement.
- Review the attached Exhibit 2.1 (Waiver of Available Cash Requirement) for the complete legal text of the amendment.
- Note that the filing references a date of "June 15, 2015" in the text describing the waiver grant, which appears to be a typographical error given the filing date of June 15, 2022; investors should verify the correct execution date in the attached exhibit.